©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2015; 7(8): 102-110
Published online Aug 15, 2015. doi: 10.4251/wjgo.v7.i8.102
Published online Aug 15, 2015. doi: 10.4251/wjgo.v7.i8.102
Neoadjuvant or adjuvant therapy for gastric cancer
Laurent Quéro, Sophie Guillerm, Christophe Hennequin, Department of Radiation Oncology, Saint Louis Hospital, 75010 Paris, France
Author contributions: Quéro L designed, researched and analyzed the literature, and helped write the paper; Guillerm S and Hennequin C analyzed the literature, and helped write the paper.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Correspondence to: Laurent Quéro, MD, PhD, Department of Radiation Oncology, Saint Louis Hospital, 1 Avenue Claude Vellefaux, 75010 Paris, France. laurent.quero@sls.aphp.fr
Telephone: +33-142-499034 Fax: +33-142-494081
Received: March 10, 2015
Peer-review started: March 13, 2015
First decision: April 13, 2015
Revised: May 8, 2015
Accepted: July 11, 2015
Article in press: July 14, 2015
Published online: August 15, 2015
Processing time: 156 Days and 22.4 Hours
Peer-review started: March 13, 2015
First decision: April 13, 2015
Revised: May 8, 2015
Accepted: July 11, 2015
Article in press: July 14, 2015
Published online: August 15, 2015
Processing time: 156 Days and 22.4 Hours
Core Tip
Core tip: Gastric cancer (GC) treatment is controversy, particularly between Asia and Western countries. In this paper, we have performed a systematic and up-to-date review of resectable GC treatment strategies and discussed different treatment options. We have also discribed ongoing clinical randomized phase 3 trials and future directions in GC treatment.